Konstantinos Z. Vardakas

ORCID: 0000-0001-9959-2242
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Antibiotic Resistance in Bacteria
  • Antibiotics Pharmacokinetics and Efficacy
  • Pneumonia and Respiratory Infections
  • Antimicrobial Resistance in Staphylococcus
  • Bacterial Identification and Susceptibility Testing
  • Antibiotic Use and Resistance
  • Nosocomial Infections in ICU
  • Clostridium difficile and Clostridium perfringens research
  • Urinary Tract Infections Management
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Neutropenia and Cancer Infections
  • Streptococcal Infections and Treatments
  • Antifungal resistance and susceptibility
  • Microscopic Colitis
  • Respiratory Support and Mechanisms
  • Orthopedic Infections and Treatments
  • Fungal Infections and Studies
  • Mycobacterium research and diagnosis
  • Vibrio bacteria research studies
  • Inhalation and Respiratory Drug Delivery
  • Respiratory viral infections research
  • scientometrics and bibliometrics research
  • Surgical site infection prevention
  • Infective Endocarditis Diagnosis and Management
  • Cystic Fibrosis Research Advances

Alfa Institute of Biomedical Sciences
2010-2021

Henry Dunant Hospital
2005-2019

IASO General Hospital
2014-2017

Chinese People's Liberation Army
2015

Mitera Hospital
2012-2014

Tufts University
2005-2014

General Hospital of Athens G. Genimatas
2009

University General Hospital Attikon
2007

Maya Educational Foundation
2006

EuroSpine
2006

We evaluated the number of deaths attributable to carbapenem-resistant Enterobacteriaceae by using studies from around world published before April 9, 2012. Attributable death was defined as difference in all-cause between patients with infections and those carbapenem-susceptible infections. Online databases were searched, data qualitatively synthesized pooled a metaanalysis. Nine met inclusion criteria: 6 retrospective case-control studies, 2 cohort 1 prospective study. Klebsiella...

10.3201/eid2007.121004 article EN cc-by Emerging infectious diseases 2014-05-21

Linezolid containing regimens have been proposed as potentially valuable alternatives for the treatment of patients with multidrug-resistant tuberculosis (MDR-TB) or extensively drug-resistant TB (XDR-TB).A systematic review and meta-analysis was conducted to assess efficacy, safety tolerability linezolid (DR-TB) treatment. We searched Cochrane Controlled Trial Registry, PubMed, Embase, Science Citation Index Expanded (SCI) China National Knowledge Infrastructure (CNKI), database up May 2014...

10.3978/j.issn.2072-1439.2015.03.10 article EN PubMed 2015-04-01

Cefiderocol (S-649266), a siderophore cephalosporin, utilizes novel mechanism of entry into the periplasmic space Gram-negative bacteria and is broadly stable to ESBLs carbapenemases.A collection carbapenem-resistant isolated from clinical specimens in 18 Greek hospitals was tested for susceptibility cefiderocol, meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin tigecycline. Broth microdilution plates were used...

10.1093/jac/dkx049 article EN Journal of Antimicrobial Chemotherapy 2017-03-20

We evaluated the published data for incidence, characteristics and outcomes of patients with community-acquired pneumonia (CAP) due to methicillin-resistant Staphylococcus aureus (MRSA). The estimated incidence MRSA CAP is 0.51–0.64 cases per 100,000. identified 74 articles reporting on 114 patients. Influenza like symptoms was reported in 41% Pneumonia improved 59 (54.1%) out 109 patients; 49 (44.5%) 110 died. duration hospitalisation 38.1±24.9 8.3±11.7 days, respectively. intensive care...

10.1183/09031936.00041009 article EN European Respiratory Journal 2009-06-18
Coming Soon ...